[MOL] New Drug May Rival Tamoxifen [00981] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] New Drug May Rival Tamoxifen



New Drug May Rival Tamoxifen 
    [05/22/2000; Reuters News Service]

NEW ORLEANS (Reuters) - Researchers said on Sunday they had shown
a cheaper new drug might rival the breast cancer drug tamoxifen,
giving women more options in their treatment. The drug, Fareston,
marketed by Kentucky-based Shire Roberts under the generic name
toremifene, is in the same class as tamoxifen. A trial of 899
patients showed the two drugs worked about equally well in women
past menopause who had undergone surgery for the same stage of
breast cancer. The patients were followed for a little over three
years on average. ``The results of this study are of significant
importance because they show that Fareston is as effective as
tamoxifen in the adjuvant treatment of breast cancer,'' Dr. Kaija
Holli, an oncologist at Tampere University Hospital in Finland
who led the study, said in a statement.

The two groups had the same rate of side effects such as sweating and
hot flashes and about the same time to breast cancer recurrence. But an
initial analysis, presented at the annual meeting of the American
Society of Clinical Oncology (ASCO), suggested that the rate at which
breast cancer recurred and the death rate from breast cancer was
slightly lower among the women who got Fareston as compared to
tamoxifen.

The full article can be found at:

http://dailynews.yahoo.com/h/nm/20000522/hl/drug_1.html
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------